[Editorial] New interventions offer prostate cancer hope

Prostate cancer is one of the most common cancers worldwide, with about 1 ·1 million cases diagnosed annually. Depending on the stage of disease at diagnosis, prostate cancer can be managed with combinations of active surveillance, surgery, radiotherapy, and androgen-deprivation therapy (ADT). However, some men have aggressive disease, in which rising concentrations of p rostate-specific antigen (PSA) herald biochemical relapse and metastatic disease, even after treatment. Currently, no standard treatment is available for these men; however, promising new data from two trials presented at the 2018 ASCO Genitourinary Cancers Symposium (Feb 8–10, 2018, San Francisco , CA, USA) suggest that this situation might be about to change.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: Editorial Source Type: research